Company
Kantar Media
Findings that rest on exhibits naming this entity
- INF-1.6: A 2019 JAMA study reports that direct-to-consumer prescription-drug advertising grew from $1.3 billion (79,000 ads) in 1997 to $6 billion (4.6 million ads, 663,000 of them TV commercials) in 2016, in 2016 dollars, and that FDA violation letters for misleading drug marketing fell from 156 to 11.
- INF-1.10: A study matching Kantar advertising by auto manufacturers to newspaper coverage of car safety recalls from 2000 to 2014 finds that newspapers cover recalls by their advertisers less, especially severe recalls. A one standard deviation increase in a large advertiser's spending over the prior two years reduces recall coverage by 24 percent for the average newspaper.
- INF-1.12: A manuscript matching Kantar newspaper advertising by drug manufacturers to 81,656 newspaper articles on drugs from 1999 to 2012 reports that a newspaper receiving an additional $100,000 from a drug's maker in the prior 14 days was 9 to 20 percent less likely to mention that drug's side effects and 23 to 33 percent less likely to report an FDA safety alert about it. The manuscript's publication venue and peer-review status are unverified.
Exhibits naming this entity
- Exhibit 992 January 2019. Schwartz LM, Woloshin S, JAMA 321(1):80-96 (Dartmouth Institute): Medical Marketing in the United States, 1997-2016
- Exhibit 993 undated (file name DTCA-2019). Focke F, Niessen-Ruenzi A, Ruenzi S, University of Mannheim: Pharmaceutical advertising biases media reports on drug safety (manuscript)
- Exhibit 994 October 2017. Beattie G, Durante R, Knight B, Sen A, National Bureau of Economic Research: Advertising Spending and Media Bias: Evidence from News Coverage of Car Safety Recalls, NBER Working Paper 23940